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Abstract
Inflammation and degradation of bone are two closely linked
processes. Chronic inflammatory arthritis not only leads to inflam-
matory bone loss but it also involves local erosion of articular bone.
This osteo-destructive feature of chronic inflammatory arthritis is a
major cause of disability in patients with rheumatoid arthritis.
Osteoclasts are essential for the resorption of mineralized cartilage
and subchondral bone in chronic arthritis. The observed up-
regulation of osteoclast differentiation factors (receptor activator of
nuclear factor-κB ligand [RANKL]) in the synovial membrane of
chronically inflamed joints indicates that osteoclasts are abundant
in this setting, leading to rapid degradation of mineralized tissue.
Blockade of osteoclast formation is thus a key strategy in
preventing structural damage in arthritis. Denosumab, a humanized
antibody that neutralizes RANKL, is an attractive candidate agent
to inhibit inflammatory bone loss.
Introduction
Pathologic changes in bone mass and bone quality can be the
manifestation of an intrinsic, often genetically based
dysfunction of the skeletal system, which can lead to fragile or
otherwise altered bone. Osteogenesis imperfecta or Paget’s
disease are among the best known examples of primary
genetically based bone disease; the former leads to fragile
bone and the latter to increased bone mass. More frequently,
however, bone becomes the target of extraskeletal processes,
and changes in the exogenous or endogenous environment
can affect skeletal tissue, accelerate bone loss, and decrease
bone quality. Lack of mobility, smoking, and drug therapy are
well established exogenous environmental factors that affect
bone quality. Endogenous factors include age-induced loss of
muscular strength and endocrine changes, such as reduction
in sex hormones during the menopause or dysfunction of the
thyroid or adrenal hormone axis.
Systemic inflammation is a key example of a condition that
profoundly affects the skeleton but is not a primary disorder
of bone itself. Recent data suggest that even a minor and
subclinical increase in systemic inflammation precipitates
bone disease and increases fracture risk [1]. This tight
interaction between inflammation and bone is highlighted by
the observation that virtually all chronic inflammatory
diseases, particularly rheumatic disease and chronic inflam-
matory bowel disease, are associated with a high prevalence
of osteoporosis and increased fracture risk [2-6]. In the case
of a more localized inflammatory process, these systemic
effects on bone are accompanied by local bone damage at
the skeletal sites closest to the inflammatory focus. Similar to
destruction mediated by an earthquake, bone damage is
most common and most severe in the vicinity of the
(inflammatory) epicenter, whereas the effects are less severe
at sites distant from the epicenter, although they can still be
detected (for instance, bone density measurements in the
case of bone loss). Local resorption of alveolar bone in
periodontal disease is a good example of local bone loss;
another clinically important example is bone erosion in
inflammatory arthritis.
Local bone erosion in arthritis
Only few diseases lead to local resorption of bone. Apart
from tumor metastases, various granulomatous diseases
(including tuberculosis, sarcoidosis, and histiocytosis) can
precipitate local bone erosion. One of the most frequent
causes for local bone erosion, however, is arthritis, which
involves destruction of juxta-articular bone. This process is a
hallmark of rheumatoid arthritis (RA) but it also occurs within
the context of other chronic forms of arthritis, particularly in
psoriatic arthritis (Figure 1). Determination of bone erosion is
almost exclusively based on radiographic findings, because
direct assessment of these lesions through biopsy is only
rarely practical. The term ‘bone erosion’ describes loss of
mineralized tissue at juxta-articular sites, which is commonly
associated with a break in the cortical lining.
Signs of inflammatory bone erosion have been found in
skeletal remains of individuals from several Indian tribes in
Northern America [7]. Destruction of bone by arthritis was
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first described more than 100 years ago. These earliest
studies used histopathologic examination to investigate areas
of structural joint damage [8]. Later, with the development of
radiographic imaging, bone erosions could be visualized
directly and became not only part of the diagnostic criteria for
RA but also a valuable tool for monitoring disease [9,10].
Virtually all clinical studies of anti-inflammatory and immuno-
modulatory drugs for the treatment of RA have employed
clinical end-points as efficacy measures and radiologic end-
points to define drug effects on structural damage.
Importantly, the resorption of mineralized tissue that is evident
on conventional radiographs is strongly associated with poor
functional outcome in patients with chronic arthritis [11-13].
With the ultimate aim being to preserve functional status and
joint architecture in RA patients, characterization of early
disease has been an important goal in RA research over the
past 10 years. It soon became evident that bone erosion
starts early in disease and progresses most rapidly during the
first year [14]. These findings have fostered the concepts that
retardation, arrest, or even repair of structural damage should
be considered central goals in the treatment of RA.
Cartilage and bone erosion are different
The early and rapid occurrence of structural damage in RA
originates from a close interaction of the synovial membrane
of the joint cavity and of the tendon sheaths with cartilage
and subchondral bone. By definition, synovial tissue becomes
inflamed during the course of arthritis and simultaneously
involves adjacent cartilage and bone. In particular, synovial
tissue close to the joint ends plays a central role in initiating
structural damage [15]. Studies of joints from animals and
humans have shown that this layer of mineralized cartilage is
rapidly resorbed, whereas the unmineralized surface cartilage
remains intact for a certain period of time.
Invasion into mineralized cartilage is a multicellular process,
involving inflammatory cells such as fibroblasts, lymphocytes,
and monocytes (Figure 2). The two former cell types trigger
differentiation of monocytes to osteoclasts, which can
remove mineral as well as matrix (either dominated by
collagen type II in the case of mineralized cartilage or rich in
collagen type I in the case of subchondral bone; Figure 3)
[16,17]. The particular susceptibility of mineralized cartilage
to osteoclast-mediated bone resorption is intuitive because
the most abundant pathway of ossification, namely
enchondral ossification, involves removal of mineralized
cartilage and its remodeling into bone. Resorption of the
subchondral bone layer also requires osteoclasts, which
depend on the presence of minerals to exert their resorptive
actions. In contrast to these mineralized tissues, resorption of
unmineralized surface cartilage is not an osteoclast-
dependent process. Although the molecular mechanisms of
degradation of surface cartilage in the inflamed joint are not
fully understood, invasion of synovial fibroblasts into the
cartilage and expression of matrix-degrading enzymes (for
instance, aggrecanases and matrix metalloproteinases) by
synovial fibroblasts, neutrophils, and chondrocytes are key
processes in cartilage damage [18]. Joint destruction can
thus be considered a process that combines several different
events: destruction of surface cartilage, resorption of
mineralized cartilage, and erosion of bone. The radiologic
image of structural damage represents a picture in which
these processes are fused.
RANKL in arthritis
The observations that osteoclasts are an integral part of the
mixed cellular infiltrate of inflammatory arthritis and that
accumulation of these cells at sites of structural damage
suggest that molecules involved in osteoclast formation are
important players in the destructive processes of the disease.
Receptor activator of nuclear factor-κB ligand (RANKL) exists
in two different isoforms: a transmembrane cell-bound form
Figure 1
Hand radiograph of a patient with rheumatoid arthritis. Imaged is the
hand of a patient with advanced rheumatoid arthritis with severe
destruction of the joint architecture. Asterisks indicate bone erosion.
Figure 2
Microphotograph of human bone erosion. Tartrate acid phosphatase
staining through a finger joint of patient with rheumatoid arthritis shows
osteoclasts (inset) resorbing the mineralized cartilage.Page 3 of 6
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and a soluble from, which shares structural similarities with
tumor necrosis factor (TNF) but which binds to a different
receptor, termed receptor antagonist of nuclear factor-κB
(RANK) [19]. Interaction of lower affinity with another
member of the TNF receptor family, namely TNF-related
apoptosis-inducing ligand, has also been described. The
interaction between RANKL and RANK is crucial for osteoclast
formation as well as lymph node organogenesis [19].
Mice that are unable to express either RANKL or RANK are
osteopetrotic because of a complete lack of osteoclasts.
These animals also exhibit complete developmental arrest of
the lymph node anlagen during embryogenesis [20,21].
Inhibition rather than absence of RANKL is achieved by over-
expression of the natural inhibitor of RANK/RANK, namely
osteoprotegerin (OPG). Whereas lymph node anlagen
develop normally in mice that over-express OPG, the bone
phenotype is very similar to that in RANKL and RANK
knockout mice, because these animals have few osteoclasts
and are osteopetrotic [22]. Also, preclical studies of RANKL
inhibition demonstrated normal immune responses [23].
RANKL is expressed in synovial tissue in chronic inflammatory
arthritides such as RA and psoriatic arthritis [24-27]. Expres-
sion can be found on T and B cells and on synovial fibro-
blasts. Importantly, many proinflammatory cytokines, including
TNF, IL-1, IL-6, and IL-17, are important inducers of RANKL
expression, as is prostaglandin E2 [28]. This plethora of
inflammatory mediators in arthritis facilitates expression of
RANKL, which engages its ligand RANK on monocytic cells,
a population that is abundant in inflammatory synovial tissue.
Formation of osteoclasts and their precursor cells is thus
rapid, early, and triggered by continuous cytokine production
and cell influx. In accordance with this, kinetic analyses of
osteoclast formation in animal models of arthritis have
revealed that cells form only a few days after the onset of
inflammation [29].
Effects of RANKL in experimental arthritis
The role played by RANKL in inflammatory bone destruction
has been intensively characterized in experimental models of
arthritis. In particular, mouse models with a genetic block in
osteoclast formation have permitted new insights into the
mechanisms of arthritis. For example, osteopetrotic mice
such as c-fos-/- mice, RANKL-/- mice, and RANK-/- mice
develop arthritis but do not exhibit bone erosion [30-32]. This
switch from a destructive to a nondestructive phenotype not
only proves that osteoclasts play a role in destruction of the
joint architecture, but it also hints that blockade of RANKL
might serve as an interesting approach to preventing
inflammatory bone erosion.
OPG has been used as a neutralizing agent to achieve
pharmacologic blockade of RANKL in various models.
Destruction of mineralized tissue was effectively blocked by
this form of RANKL inhibition in models including adjuvant-
induced arthritis, TNF-mediated arthritis, and collagen-
induced arthritis [33-36]. In contrast, OPG did not ameliorate
the inflammatory signs of disease, and histologic examination
of inflamed joints from these models revealed full-blown
development of synovial inflammation, suggesting that the
interaction between RANKL and RANK is not critically
involved in joint inflammation. Despite the presence of
inflammation, however, structural damage did not occur to a
significant degree in these models, indicating that RANKL-
mediated osteoclast formation is a key player in structural
damage in arthritis. Treatment with OPG completely blocked
osteoclast formation in inflammatory tissue and prevented the
formation of osteoclast precursor cells (Figure 4). This arrest
of osteoclast differentiation elicited by OPG, together with
the effect on function of mature osteoclasts, is crucial to
appreciating the effective bone-sparing properties of RANKL
blockade. Given the abundance of monocytes as potential
osteoclast precursors in the inflammatory tissue and the large
number of cells that actually differentiate from this precursor
pool to the osteoclast lineage, this dual inhibitory effect on
both differentiation and activation of osteoclasts can be
considered an important feature of RANKL blockade. This
may provide an explanation as to why relatively high amounts
of bisphosphonates are necessary to block inflammatory
bone erosions in animal models of arthritis [37]. Also, the
uptake and deposition of bisphosphonates at cortical bone
sites affected by arthritis might be insufficient to allow
complete protection of bone.
It is not entirely clear whether RANKL blockade also affects
proteoglycan loss in superficial articular cartilage. There is no
doubt that targeting of osteoclasts would protect mineralized
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Figure 3
Scheme of arthritic bone erosion. In synovial inflammatory tissue the
interaction of fibroblasts, T cells, and monocytes leads to differentiation
of osteoclast precursor cells and mature osteoclasts; this results in
destruction of mineralized tissue, including cartilage and cortical bone.cartilage, an area that is highly sensitive to osteoclast-
mediated resorption. Nonmineralized cartilage is not affected
by osteoclasts, and it is therefore unlikely that RANKL
blockade would affect this compartment directly. In some of
the experimental arthritis models, however, protection against
proteoglycan loss was observed following RANKL blockade,
whereas it has not been observed in others. There are two
potential explanations for the protection of surface cartilage
after RANKL blockade. The first of these is a direct effect of
RANKL blockade on cartilage by engagement of RANKL and
RANK, which are expressed on articular chondrocytes [38].
However, a specific function of RANK/RANKL on chondro-
cytes remains to be defined. A second possibility is an
indirect protective effect on cartilage, based on prevention of
resorption of mineralized cartilage attached to surface
cartilage. Replacement of this interaction by an inflammatory
tissue that attacks unmineralized cartilage not only from the
surface (joint cavity) but also at the base may create a forceps-
like destruction pattern that could dramatically affect the
structure of this remaining surface cartilage. In this regard,
inflammatory tissue not only creates aggrecanases and matrix
metalloproteinases, which destroy the cartilage matrix, but it
also leads to internal production of these enzymes by
chondrocytes through the expression of proinflammatory
cytokines. Thus, RANKL blockade probably affects the
microenvironment of articular cartilage in inflammatory arthritis
by preserving surrounding mineralized cartilage and bone.
RANKL inhibition in human arthritis
Blockade of RANKL is considered a powerful future anti-
resorptive strategy for the treatment of human bone disease.
First proof of principal for this concept was derived from use
of Fc:OPG as a blocker of RANKL; a single injection of this
protein in humans resulted in increased bone mass and rapid
decline in bone resorption parameters [39]. This study was
conducted in postmenopausal women with low bone mass.
Recently, a fully human neutralizing antibody directed against
RANKL, namely denosumab (formerly known as AMG 162),
was developed that has sustained antiresorptive activity,
lasting for up to 6 months after a single injection [40].
Repeated injections of this antibody have resulted in
profound and significant increases in bone mass at both axial
and peripheral skeletal sites, as well as in trabecular and
cortical areas of bone [41]. Thus far, no major adverse effects
of denosumab have been reported; this is reassuring, but
further careful and long-term surveillance of infection rate and
cardiovascular events are needed before conclusions
regarding the long-term safety of this drug can be drawn.
These findings make denosumab an attractive therapeutic
tool for treating patients with RA. It is conceivable that the
effects of denosumab extend not only to the prevention and
treatment of generalized bone loss in RA but also to the
prevention and treatment of joint destruction. A phase II study
is currently underway that aims to investigate the role of
RANKL blockade in inhibiting structural damage in RA, and
preliminary data suggest that denosumab can indeed inhibit
the process of bone erosion, as detected by magnetic
resonance imaging of joints [42].
Although RANKL blockade does not inhibit inflammation,
necessitating its combination with anti-inflammatory therapy,
there are several rationales for targeting RANKL in human RA.
First, structural damage often progresses despite use of
disease-modifying antirheumatic drugs, especially in those
patients who are not treated with TNF blockers. Second,
structural damage is a leading cause of decreased joint
function and disability in RA patients, emphasizing the need
for effective drug therapy to preserve joint architecture.
Finally, targeting of RANKL specifically and directly affects
the mechanism responsible for the loss of mineralized
cartilage and bone in chronic arthritis.
Conclusion
Chronic arthritis is an osteodestructive process, which leads
to an accumulation of joint damage over time and prevents a
restitutio ad integrum, as observed in spurious forms of
arthritis. In addition to controlling inflammation, prevention of
structural damage is a key objective of antirheumatic therapy.
Because structural damage in RA is based on formation of
osteoclasts in and around the joint, which resorb mineralized
cartilage and subchondral bone, and because generation of
these cells depends on RANKL, inhibition of this molecule is
an interesting way to improve therapeutic outcomes in RA.
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Figure 4
Effect of RANKL blockade on experimental arthritis. Adjuvant-induced
arthritis of rats treated with vehicle or osteoprotegerin (OPG). Note the
protection of bone and the absence of (stained) osteoclasts. RANKL,
receptor activator of nuclear factor-κB ligand.References
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